Navigation Links
Variation Biotechnologies Names Jeff Baxter CEO
Date:9/22/2009

CAMBRIDGE, Mass., Sept. 22 /PRNewswire/ -- Variation Biotechnologies Inc. today announced the appointment of Jeff Baxter as chief executive officer. Baxter will be based at the company's new U.S. headquarters in Cambridge, Mass.

Baxter, 48, replaces Francisco Diaz-Mitoma, M.D., Ph.D., a founder of the company who will remain a Board member and transition to chief scientific officer and president of Canadian operations. With a track record of more than two decades of outstanding success in the biotechnology and pharmaceuticals industries, Baxter has experience ranging from management operations to finance and business development and venture capital. Baxter will also join the company's board of directors.

"Jeff's extensive Big Pharma experience combined with his expertise in founding and operating early stage biotechnology companies make him an ideal leader of the Variation senior management team as we advance our two novel vaccine platforms into clinical development," said Diaz-Mitoma.

Baxter added: "I look forward to leading a highly distinguished team that is on track to begin clinical development with three vaccines in the next 12 months. I am particularly excited about the company's proprietary oral vaccine platform, which has demonstrated proof of concept with several different antigens in multiple preclinical models."

Prior to joining Variation, Baxter was a managing partner of venture capital firm The Column Group, which has to date founded six platform and pipeline-based biotechnology companies. Notably, he played a pivotal role in the creation of Immune Design Corp., a vaccine company based on the Lentiviral vector platform and TLR adjuvant technologies.

Prior to The Column Group, Baxter held a variety of executive positions with GlaxoSmithKline (GSK), including senior vice president, R&D finance and operations; vice president of competitive excellence, office of the CEO; and head of finance, worldwide manufacturing and supply. His most recent position in R&D included responsibility for finance, pipeline resource planning and allocation, business development deal structuring and SROne (GSK's in house $125 million venture capital fund). He also chaired GSK's R&D operating board. Prior to GSK, Baxter worked at Unilever and British American Tobacco.

Baxter was educated at Thames Valley University, University of Bradford Management School and London Business School and is a Fellow of the Chartered Institute of Management Accountants (FCMA).

Variation Biotechnologies Inc. (VBI) is a leader in the discovery and development of novel vaccines to fight infectious diseases, including seasonal and pandemic influenza, hepatitis and HIV. The company utilizes its proprietary VariositeTM technology to design vaccines with broad immunity and is also developing a proprietary technology to enable convenient oral administration. VBI's lead candidates include a multi-season parenteral vaccine to fight influenza and an orally delivered vaccine to address hepatitis A. For more information please visit Variation's Web site, www.variationbiotech.com.

    Contact:  Tracey Milani, Ph.D., or Tony Russo, Ph.D.
              Russo Partners
              (646) 651-5366
              tracey.milani@russopartnersllc.com
              tony.russo@russopartnersllc.com


'/>"/>
SOURCE Variation Biotechnologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Matrix Genomics, Elizabeth Corder, PhD - Gene Variation in the LRRK2 Gene and High Risk for Parkinson's Disease
2. Chromosome breakpoints contribute to genetic variation
3. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
4. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
5. Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases
6. Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
7. Consortium publishes Phase II map of human genetic variation
8. New method of selecting DNA for resequencing accelerates discovery of subtle DNA variations
9. 454 sequencing uncovers significant genetic variation
10. 454 Sequencing(TM): Science Paper Suggests That Structural Variation Plays an Important Role in Genetic Variation
11. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... ... to nourishing a range of emerging bio and technology start-ups, is hosting “Celebration ... 2017. This double event will start with libations and networking at 3:30 p.m. ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... new webinar will explore challenging patient cases when screening for direct oral anticoagulant. ... may be a need for bridging parental anticoagulation especially for those at high ...
(Date:4/20/2017)... 2017  Eli Lilly and Company (NYSE: ... for the prevention of migraine at the American Academy ... April 22-28, 2017, in Boston . ... AAN, including safety and patient outcomes data for galcanezumab ... reduction in monthly migraine headache days among patients with ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... scientific and clinical research community’s growing body of knowledge during its Eighth ... Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, graduate students, ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):